CAMZYOS® Study Designs for EXPLORER-HCM and EXPLORER-LTE

On this page:         EXPLORER-HCM          EXPLORER-‍LTE

EXPLORER-HCM: Study Design

EXPLORER-HCM: A Groundbreaking Phase 3 Trial for Symptomatic NYHA Class II–III Obstructive HCM1,2

A randomized, double blind, placebo-controlled trial evaluated the efficacy and safety of CAMZYOS vs placebo1,2

EXPLORER-HCM clinical trial study design

92%

of patients were on background
therapy with BBs or CCBs2*

CAMZYOS (n=119/123) | Placebo (n=112/128)

*Patients on BBs or CCBs were allowed to continue background therapy.2

See select baseline patient characteristics below >

The primary composite functional endpoint and hierarchical secondary endpoints were designed to assess treatment parameters for symptomatic NYHA class II–III obstructive HCM2

Primary composite functional endpoint measured change from baseline to Week 30 in symptoms (NYHA) and functional capacity (pVO2)1,2

EXPLORER-HCM primary composite functional endpoints

Primary composite functional endpoint explained >

Hierarchical secondary endpoints1,2†:
(Measured from baseline to Week 30)

  • Change in post-exercise LVOT gradient
  • Change in pVO2
  • Proportion of patients with ≥1 NYHA class improvement
  • Change in KCCQ-23–CSS
  • Change in HCMSQ-SoB

Select prespecified exploratory endpoints1,2:
(Not powered for statistical significance)

  • Post-exercise LVOT peak gradient <50 mm Hg
  • Post-exercise LVOT peak gradient <30 mm Hg
  • Proportion of patients with reductions in serum concentrations of N⁠-⁠terminal pro B-‍type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I (hs-cTnI)
† All assessments for secondary endpoints were performed and Type I error was controlled in hierarchical order (sequence as indicated above) upon achieving significance in the primary endpoint (with two tailed P<0.05 required to proceed).2

HCM=hypertrophic cardiomyopathy; HCMSQ-SoB=Hypertrophic Cardiomyopathy Symptom Questionnaire Shortness of Breath subscore; KCCQ-23–CSS=Kansas City Cardiomyopathy Questionnaire (23-item version)–Clinical Summary Score; LVOT=left ventricular outflow tract; NYHA=New York Heart Association; pVO2=peak oxygen consumption; SRT=septal reduction therapy.

Select baseline patient characteristics in EXPLORER-HCM1,2

Select baseline patient characteristics
Values in the table are mean ± SD, n (%) CAMZYOS (n=123) Placebo (n=128)
Age, mean (SD), years 59 (12.2) 59 (11.8)
Women, n (%) 57 (46) 45 (35)
Race, n (%)
White 115 (94) 114 (89)
Black or African American 1 (1) 5 (4)
American Indian or Alaska Native 0 1 (1)
Asian 4 (3) 2 (2)
Unknown 3 (2) 6 (5)
Background HCM treatment, n (%)
Beta blocker
Calcium channel blocker‡		 94 (76)
25 (20)		 95 (74)
17 (13)
NYHA class, n (%)
Class II
Class III		 88 (72)
35 (28)		 95 (74)
33 (26)
pVO2 mean (SD), mL/kg/min 18.9 (4.9) 19.9 (4.9)
LVOT gradient at baseline, mean (SD), mmHg
Valsalva
Post-exercise§		 72 (32)
86 (34)		 74 (32)
84 (36)
LVEF, mean (SD), (%) 74 (6) 74 (6)
Critical cardiac history
Atrial fibrillation, n (%) 12 (10) 23 (18)
Implantable cardioverter-‌defibrillator, n (%) 27 (22) 29 (23)
Prior invasive SRT, n (%) 11 (9) 8 (6)
‡ Nondihydropyridine calcium channel blockers.2
§ Data missing for one patient in the CAMZYOS group and one patient in the placebo group.2

SD=standard deviation.

Study procedures used in EXPLORER-HCM to determine the efficacy and safety of CAMZYOS

Open for study procedures >

EXPLORER-LTE: Study Design

EXPLORER-LTE: A Cohort of MAVA-LTE, a 5-Year Extension Designed to Evaluate Long-Term Safety, Efficacy, and Clinically Guided Dosing for CAMZYOS3-6

To be eligible to enroll in the EXPLORER-LTE cohort of MAVA-LTE, patients had to complete EXPLORER-HCM, including the 8-‍week washout period. Of the 251 patients|| who completed EXPLORER-HCM, 231 enrolled in MAVA-LTE in the EXPLORER-LTE cohort, which is being evaluated in a single-‍arm trial without an active comparator.

LTE trial objectives assessed long-term effects of CAMZYOS4

  • Primary objective: Safety and tolerability

  • Secondary objectives: Changes in NYHA class, LVOT gradients at rest and with Valsalva, and LVEF 

  • Exploratory objectives: Changes in NT-proBNP and measures of left ventricle filling

EXPLORER-LTE 5-Year Study Design
|| Patients enrolled in EXPLORER-LTE were part of either the CAMZYOS or placebo arm in the EXPLORER-HCM trial.3-6
This is not consistent with the current approved dosing schedule per the U.S. Full Prescribing Information.1

EOT=end of treatment; QD=once daily.

MAVA-LTE: EXPLORER-LTE cohort study limitations and additional information:

  • These data are not included in the CAMZYOS U.S. Full Prescribing Information. Caution should be used in interpreting the data as data were not statistically tested for significance but are only descriptive in nature3

  • MAVA-LTE, including the EXPLORER-LTE cohort, is a single-arm study without active comparator; patients in EXPLORER-LTE were part of either the CAMZYOS or placebo group in EXPLORER-HCM; therefore, baseline characteristics for EXPLORER-LTE changed due to time and consolidation of both arms to one cohort4

  • There are limitations with the data, including decreased sample size and different continuation rates based on the continued involvement of responders and attrition of nonresponders4

  • The EXPLORER-LTE cohort of MAVA-LTE included 14 patients who were NYHA class I at screening. These patients were included in the EXPLORER-HCM trial; 5 had received CAMZYOS, and 9 were in the placebo group3

Select Patient Baseline# Characteristics for EXPLORER-LTE3

Characteristic EXPLORER-LTE 
cohort (n=123)
Age, mean (SD), years 60.0 (11.9)
Female, n (%) 91 (39.4)
Background HCM treatment, n (%)
  • BBs
  • CCBs
176 (76.2)
38 (16.5)
NYHA class, n (%)
  • Class I
  • Class II
  • Class III
14 (6.1)
152 (65.8)
65 (28.1)
NT-proBNP, median (IQR), ng/L 766.0 (323.0, 1593.0)
[n=230]
LVOT gradient at baseline, mean (SD), mmHg
  • Resting
  • Valsalva
48.3 (31.9)
69.5 (33.3) [n=228]
LVEF, mean (SD), % 74.0 (5.9) [n=230]
Time on study, median (range), weeks 166.1 (6.0–228.1)

#Baseline is defined as last non-missing measurement before the first dose of CAMZYOS in MAVA-LTE.3
IQR=interquartile range.

Dose changes during treatment >

References:

  1. CAMZYOS [Package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2025.
  2. Olivotto I, Oreziak A, Barriales-Villa R, et al; EXPLORER-HCM study investigators. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759-769. doi:10.1016/S0140-6736(20)31792-X
  3. Garcia-Pavia P, Oreziak A, Masri A, et al. Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2024; ehae579. doi:10.1093/eurheartj/ehae579
  4. Rader F, Oręziak A, Choudhury L, et al. Mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: interim results from the MAVA-LTE study, EXPLORER-LTE Cohort. J Am Coll Cardiol. 2024;12(1):164-177.
  5. Garcia-Pavia P, Oreziak A, Masri A, et al. Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2024 [supplementary appendix]. doi:10.1093/eurheartj/ehae579
  6. Garcia-Pavia P, Oreziak A, Masri A, et al. Long-term safety and efficacy of mavacamten in obstructive hypertrophic cardiomyopathy: Up to 3.5-year follow-up results of the EXPLORER cohort of MAVA-Long-Term Extension study. Presented at European Society of Cardiology; August 30-September 2, 2024; London and online. Oral presentation 84470.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF HEART FAILURE

CAMZYOS reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction.

Echocardiogram assessments of LVEF are required prior to and during treatment with CAMZYOS. Initiation of CAMZYOS in patients with LVEF <55% is not recommended. Interrupt CAMZYOS if LVEF is <50% at any visit or if the patient experiences heart failure symptoms or worsening clinical status.

Concomitant use of CAMZYOS with certain cytochrome P450 inhibitors or discontinuation of certain cytochrome P450 inducers may increase the risk of heart failure due to systolic dysfunction; therefore, the use of CAMZYOS is contraindicated with the following:

 
  • Strong CYP2C19 inhibitors
  • Moderate to strong CYP2C19 inducers or moderate to strong CYP3A4 inducers

Because of the risk of heart failure due to systolic dysfunction, CAMZYOS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the CAMZYOS REMS PROGRAM.

CONTRAINDICATIONS

CAMZYOS is contraindicated with concomitant use of:

 
  • Strong CYP2C19 inhibitors
  • Moderate to strong CYP2C19 inducers or moderate to strong CYP3A4 inducers

WARNINGS AND PRECAUTIONS

Heart Failure
CAMZYOS reduces systolic contraction and can cause heart failure or significantly reduce ventricular function. Patients who experience a serious intercurrent illness (eg, serious infection) or arrhythmia (eg, atrial fibrillation or other uncontrolled tachyarrhythmia) are at greater risk of developing systolic dysfunction and heart failure.

Assess the patient’s clinical status and LVEF prior to and regularly during treatment and adjust the CAMZYOS dose accordingly. New or worsening arrhythmia, dyspnea, chest pain, fatigue, palpitations, leg edema, or elevations in N-terminal pro-B-type natriuretic peptide  (NT-proBNP)  may be signs and symptoms of heart failure and should also prompt an evaluation of cardiac function.

Asymptomatic LVEF reduction, intercurrent illnesses, and arrhythmias require additional dosing considerations.

Initiation of CAMZYOS in patients with LVEF <55% is not recommended. Avoid concomitant use of CAMZYOS in patients on disopyramide, ranolazine, verapamil with a beta blocker, or diltiazem with a beta blocker as these medications and combinations increase the risk of left ventricular systolic dysfunction and heart failure symptoms and clinical experience is limited.

CYP450 Drug Interactions Leading to Heart Failure or Loss of Effectiveness

CAMZYOS is primarily metabolized by CYP2C19 and CYP3A4 enzymes. Concomitant use of CAMZYOS and drugs that interact with these enzymes may lead to life-threatening drug interactions such as heart failure or loss of effectiveness.

Advise patients of the potential for drug interactions, including with over-the-counter medications (such as omeprazole, esomeprazole, or cimetidine). Advise patients to inform their healthcare provider of all concomitant products prior to and during CAMZYOS treatment.

CAMZYOS Risk Evaluation and Mitigation Strategy (REMS) Program

CAMZYOS is only available through a restricted program called the CAMZYOS REMS Program because of the risk of heart failure due to systolic dysfunction. Notable requirements of the CAMZYOS REMS Program include the following:

 
  • Prescribers must be certified by enrolling in the REMS Program
  • Patients must enroll in the REMS Program and comply with ongoing monitoring requirements
  • Pharmacies must be certified by enrolling in the REMS Program and must only dispense to patients who are authorized to receive CAMZYOS
  • Wholesalers and distributors must only distribute to certified pharmacies

Further information is available at  www.CAMZYOSREMS.com  or by telephone at  1-833-628-7367.

Embryo-Fetal Toxicity

CAMZYOS may cause fetal toxicity when administered to a pregnant female, based on animal studies. Confirm absence of pregnancy in females of reproductive potential prior to treatment and advise patients to use effective contraception during treatment with CAMZYOS and for 4 months after the last dose. Combined hormonal contraceptives (CHCs) containing a combination of ethinyl estradiol and norethindrone may be used with CAMZYOS. However, CAMZYOS may reduce the effectiveness of certain other CHCs. If these CHCs are used, advise patients to add nonhormonal contraception (such as condoms) during concomitant use and for 4 months after the last dose of CAMZYOS.

ADVERSE REACTIONS

In the EXPLORER-HCM trial, adverse reactions occurring in >5% of patients and more commonly in the CAMZYOS group than in the placebo group were dizziness (27% vs 18%) and syncope (6% vs 2%). There were no new adverse reactions identified in VALOR-HCM.

Effects on Systolic Function

In the EXPLORER-HCM trial, mean (SD) resting LVEF was 74% (6) at baseline in both treatment groups. Mean (SD) absolute change from baseline in LVEF was -4% (8) in the CAMZYOS group and 0% (7) in the placebo group over the 30-week treatment period. At Week 38, following an 8-week interruption of trial drug, mean LVEF was similar to baseline for both treatment groups. In the EXPLORER-HCM trial, 7 (6%) patients in the CAMZYOS group and 2 (2%) patients in the placebo group experienced reversible reductions in LVEF <50% (median 48%: range 35-49%) while on treatment. In all 7 patients treated with CAMZYOS, LVEF recovered following interruption of CAMZYOS.

DRUG INTERACTIONS

Potential for Other Drugs to Affect Plasma Concentrations of CAMZYOS

CAMZYOS is primarily metabolized by CYP2C19 and to a lesser extent by CYP3A4 and CYP2C9. Inducers and inhibitors of CYP2C19 and moderate to strong inhibitors or inducers of CYP3A4 may affect the exposures of CAMZYOS.

Impact of Other Drugs on CAMZYOS:

 
  • Strong CYP2C19 Inhibitors: Concomitant use increases CAMZYOS exposure, which may increase the risk of heart failure due to systolic dysfunction. Concomitant use is contraindicated
  • Moderate to Strong CYP2C19 Inducers or Moderate to Strong CYP3A4 Inducers:  Concomitant use decreases CAMZYOS exposure, which may reduce CAMZYOS’ efficacy. The risk of heart failure due to systolic dysfunction may increase with discontinuation of these inducers as the levels of induced enzyme normalizes. Concomitant use is contraindicated
  • Weak CYP2C19 Inhibitors or Moderate CYP3A4 Inhibitors: Concomitant use with a weak CYP2C19 inhibitor or a moderate CYP3A4 inhibitor increases CAMZYOS exposure, which may increase the risk of adverse drug reactions. Initiate CAMZYOS at the recommended starting dose of 5 mg orally once daily in patients who are on stable therapy with a weak CYP2C19 inhibitor or a moderate CYP3A4 inhibitor. Reduce dose of CAMZYOS by one level (ie, 15 to 10 mg, 10 to 5 mg, or 5 to 2.5 mg) in patients who are on CAMZYOS treatment and intend to initiate a weak CYP2C19 inhibitor or a moderate CYP3A4 inhibitor. Schedule clinical and echocardiographic assessment 4 weeks after inhibitor initiation, and do not up-titrate CAMZYOS until 12 weeks after inhibitor initiation. Avoid initiation of concomitant weak CYP2C19 and moderate CYP3A4 inhibitors in patients who are on stable treatment with 2.5 mg of CAMZYOS because a lower dose is not available. For short-term use (eg 1 week), interrupt CAMZYOS for the duration of treatment with a weak inhibitor of CYP2C19 or a moderate inhibitor of CYP3A4. CAMZYOS may be reinitiated at the previous dose immediately on discontinuation of concomitant therapy
  • Moderate CYP2C19 Inhibitors or Strong CYP3A4 Inhibitors: Concomitant use with a moderate CYP2C19 inhibitor or strong CYP3A4 inhibitor increases CAMZYOS exposure, which may increase the risk of adverse drug reactions. Discontinuing use of a moderate CYP2C19 inhibitor or strong CYP3A4 inhibitor after long-term concomitant use may decrease CAMZYOS exposure, which may reduce CAMZYOS’ efficacy. Initiate CAMZYOS at a starting dosage of 2.5 mg orally once daily in patients who are on a stable therapy with a moderate CYP2C19 inhibitor or a strong CYP3A4 inhibitor. Reduce dose of CAMZYOS by one level (ie, 15 to 10 mg, 10 to 5 mg, or 5 to 2.5 mg) in patients who are on CAMZYOS and intend to initiate a moderate CYP2C19 inhibitor or a strong CYP3A4 inhibitor. Avoid initiation of concomitant moderate CYP2C19 and strong CYP3A4 inhibitors in patients who are on a stable treatment with 2.5 mg of CAMZYOS because a lower dose is not available. An increase in dose of CAMZYOS may be needed if the moderate inhibitor of CYP2C19 or strong inhibitor of CYP3A4 is discontinued after long-term concomitant use. Monitor for new or worsening symptoms. For short-term use (ie, when CAMZYOS dose modification is not feasible), interrupt CAMZYOS for the duration of treatment with a weak inhibitor of CYP2C19 or a moderate inhibitor of CYP3A4. CAMZYOS may be reinitiated at the previous dose immediately on discontinuation of concomitant therapy

Potential for CAMZYOS to Affect Plasma Concentrations of Other Drugs

CAMZYOS is an inducer of CYP3A4, CYP2C9, and CYP2C19. Concomitant use with CYP3A4, CYP2C9, or CYP2C19 substrates may reduce plasma concentration of these drugs. Closely monitor when CAMZYOS is used with concomitant CYP3A4, CYP2C9, or CYP2C19 substrates unless otherwise recommended in the Prescribing Information.

Certain Combined Hormonal Contraceptives (CHCs): Progestin and ethinyl estradiol are CYP3A4 substrates. Concomitant use of CAMZYOS may decrease exposures of certain progestins, which may lead to contraceptive failure. CHCs containing a combination of ethinyl estradiol and norethindrone may be used with CAMZYOS, but if other CHCs are used, advise patients to add nonhormonal contraception (such as condoms) or use an alternative contraceptive method that is not affected by CYP450 enzyme induction (eg intrauterine system) during concomitant use and for 4 months after the last dose of CAMZYOS.

Drugs That Reduce Cardiac Contractility

Expect additive negative inotropic effects of CAMZYOS and other drugs that reduce cardiac contractility. Avoid concomitant use of CAMZYOS in patients on disopyramide, ranolazine, verapamil with a beta blocker, or diltiazem with a beta blocker as these medications and combinations increase the risk of left ventricular systolic dysfunction and heart failure symptoms and clinical experience is limited.

If concomitant therapy with a negative inotrope is initiated, or if the dose of a negative inotrope is increased, monitor LVEF closely until stable doses and clinical response have been achieved.

SPECIFIC POPULATIONS

Pregnancy

CAMZYOS may cause fetal harm when administered to a pregnant female. Advise pregnant females about the potential risk to the fetus with maternal exposure to CAMZYOS during pregnancy. There is a pregnancy safety study for CAMZYOS. If CAMZYOS is administered during pregnancy, or if a patient becomes pregnant while receiving CAMZYOS or within 4 months after the last dose of CAMZYOS, healthcare providers should report CAMZYOS exposure by contacting Bristol Myers Squibb at 1-800-721-5072 or www.bms.com.

Lactation

The presence of CAMZYOS in human or animal milk, the drug’s effects on the breastfed infant, or the effects on milk production are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for CAMZYOS and any potential adverse effects on the breastfed child from CAMZYOS or from the underlying maternal condition.

Females and Males of Reproductive Potential

Confirm absence of pregnancy in females of reproductive potential prior to initiation of CAMZYOS. Advise females of reproductive potential to use effective contraception during treatment with CAMZYOS and for 4 months after the last dose. CHCs containing a combination of ethinyl estradiol and norethindrone may be used with CAMZYOS. However, CAMZYOS may reduce the effectiveness of certain other CHCs. If these CHCs are used, advise patients to add nonhormonal contraception (such as condoms) or use an alternative contraceptive method during concomitant use and for 4 months after the last dose of CAMZYOS.

INDICATION

CAMZYOS® (mavacamten) is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) Class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.

Please see US  Full Prescribing Information, including  Boxed WARNING.

Bristol Myers SquibbTM Logo

Legal Notice     Privacy Policy     Your Privacy Choices

© 2025 MyoKardia, Inc., a Bristol Myers Squibb company. 
CAMZYOS® and the CAMZYOS and MyCAMZYOS Logos are trademarks of MyoKardia, Inc.

3500-US-2400621   04/25

This site is intended for U.S. Healthcare Professionals only.